ArticleOpen medicine (Warsaw, Poland)2024
MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE.
Xin Lu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.